¢£·Ç¼¨ÈĤËÌá¤ë¢£ Á´Éô 1- ºÇ¿·50
カスタム検索

´â·Ç¼¨ÈÄ..>³¤³°¥Ë¥å¡¼¥¹

1 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2005/05/01(Æü) 13:52
¤³¤Á¤é¤Ï³¤³°¤Î¥Ë¥å¡¼¥¹¤ò¤¢¤²¤Þ¤·¤ç¤¦¡£

¤Ç¤­¤¿¤éÆüËܸìËÝÌõ¤Î¾ðÊó¤Ã¤Æ¤³¤È¤Ç¡£(o*¡£_¡£)o¥Ú¥³¥Ã

2 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2005/05/01(Æü) 13:53
[ ľIJ´â¤ËÂФ·¤Æ°ÂÁ´À­¤ÈÍ­¸úÀ­¤È¤¬Ç§¤á¤é¤ì¤¿¥«¥Ú¥·¥¿¥Ó¥ó¤È¥¤¥ê¥Î¥Æ¥«¥ó¡ÝÊü¼ÍÀþÎÅË¡¤È¤ÎÊ»ÍÑ ]

2005-03-24 15:19:24-0400¡Ê¥í¥¤¥¿¡¼¥Ø¥ë¥¹¡Ëȯ

¥Ë¥å¡¼¥è¡¼¥¯¡Ê¥í¥¤¥¿¡¼¥Ø¥ë¥¹¡Ë¡ÝÂè­µÁê»î¸³¤Ë¤è¤ê¡¢
½µ1²ó¤Î¥¤¥ê¥Î¥Æ¥«¥ó¤ª¤è¤ÓÊü¼ÍÀþÎÅË¡¤Ë¥«¥Ú¥·¥¿¥Ó¥ó¤òÊ»ÍѤ·¤¿¾ì¹ç¡¢
ľIJ´â¤Î´µ¼Ô¤Ë¤ª¤¤¤Æ¥Õ¥ë¥ª¥í¥¦¥é¥·¥ë¡ÊFU¡Ë¤ª¤è¤Ó¥¤¥ê¥Î¥Æ¥«¥ó²½³ØÊü¼ÍÀþÎÅË¡¤ÎÊ»ÍÑÎÅË¡¤Ë
Èæ¤Ù¤ÆÆ±Åù°Ê¾å¤ÎÇ¦ÍÆÀ­¤¬¤¢¤ê¡¢²¾È¯É½Ãʳ¬¤ÎÍ­¸úÀ­¥Ç¡¼¥¿¤âÎɹ¥¤Ç¤¢¤ë¤³¤È¤¬¼¨¤µ¤ì¤Æ¤¤¤ë¡£
°ìÁص¬ÌϤÎÂ礭¤Ê¤³¤Î¼è¤êÁȤߤǤ¢¤ëÂè­¶Áê»î¸³¼Â»Ü¤¬ÀµÅö²½¤µ¤ì¤ë¤³¤È¤ò¥É¥¤¥Ä¤Ë¤¢¤ë
¥Ï¥¤¥Ç¥ë¥Ö¥ë¥¯Âç³Ø¤ÎRalf-Dieter HofheinzÇî»Î¤é¤¬¡¢
Clinical Oncology»ï¤Î3·î1Æüȯ¹Ô¹æÃæ¤Ë·ëÏÀÉÕ¤±¤Æ¤¤¤ë¡£

·Ð¸ý¥Õ¥ë¥ª¥í¥Ô¥ê¥ß¥¸¥ó¤Ç¤¢¤ë¥«¥Ú¥·¥¿¥Ó¥ó¤Ï¡¢¾Ã²½´É¤Î°­À­¼ðáç¤Ë¤ª¤±¤ëFU¤Ø¤ÎÂåÂØÌô¤È¤·¤Æ¤Î
»ÈÍѤ¬Áý²ÃÃæ¤Ç¤¢¤ë¤ÈƱÇî»Î¤é¤¬½Ò¤Ù¤Æ¤¤¤ë¡£
¤³¤Î·Ð¸ýÌô¤ÏFUÀÅÃí¤ËÈæ¤Ù¤Æ°ÂÁ´À­¤¬¹â¤¤°ìÊý¡¢Êü¼ÍÀþÎÅË¡¤ÈÁê¾èŪ¤ËºîÍѤ¹¤ë¤ÈƱÇî»Î¤é¤ÏÄɵ­¤·¤Æ¤¤¤ë¡£

¥¤¥ê¥Î¥Æ¥«¥ó¤Ë¤âÊü¼ÍÀþÁý´¶ºîÍѤ¬¤¢¤ê¡¢FU¤È¤ÎÊ»ÍѤ¬Ä¾Ä²´â¤ËÂФ¹¤ëɸ½àÎÅË¡¤È¤Ê¤Ã¤Æ¤¤¤ë¤È
ƱÇî»Î¤é¤Ï³¤±¤Æ¤¤¤ë¡£Â¿¤¯¤Î¸¦µæ¤¬Ä¾Ä²´â¤ËÂФ¹¤ë¥¤¥ê¥Î¥Æ¥«¥ó¡¢
FU¤ª¤è¤ÓÊü¼ÍÀþÎÅË¡¤òɾ²Á¤·¤Æ¤­¤¿°ìÊý¤Ç¡¢¥«¥Ú¥·¥¿¥Ó¥ó¡¢¥¤¥ê¥Î¥Æ¥«¥ó¡ÊCAPIRI¡Ë¤È
Êü¼ÍÀþÎÅË¡¤òÊ»ÍѤ·¤¿¾ì¹ç¤ÎÍ­¸úÀ­¤ËÂФ¹¤ë¥Ç¡¼¥¿¤Ï¤³¤ì¤Þ¤Ç¤Ëȯɽ¤µ¤ì¤Æ¤¤¤Ê¤¤¡£

ƱÇî»Î¤é¤Ï¸½¹Ô¤Î»î¸³¤ò¼Â»Ü¤·¤Æ¡¢¶É½ê¤Ë¿Ê¹Ô¤·¤¿Ä¾Ä²Á£´â¤òÍ­¤¹¤ë´µ¼Ô19̾¤Ë¤ª¤¤¤Æ½ÑÁ°ÎÅË¡¤È¤·¤Æ
¤ÎCAPIRI¤ÈÊü¼ÍÀþÎÅË¡¤È¤òɾ²Á¤·¤¿¡£¤³¤ì¤é¤Î´µ¼Ô¤ÏÊü¼ÍÀþÎÅË¡¤Î1»þ´ÖÁ°¤Ë
¥¤¥ê¥Î¥Æ¥«¥ó50 mg/­Ö¤ò½µ1²ó5½µ´ÖÅêÍ¿¤µ¤ì¡¢Â³¤¤¤Æ¥«¥Ú¥·¥¿¥Ó¥ó¤ò·Ð¸ý¤Ç1Æü2²óÅêÍ¿¤µ¤ì¤¿¡£
¥«¥Ú¥·¥¿¥Ó¥ó¤ÎÍÑÎ̤Ï500 mg/­Ö1Æü2²ó¡¢625 mg/­Ö1Æü2²ó¤Þ¤¿¤Ï750 mg/­Ö1Æü2²ó¤«¤é¤Ê¤ë3¼ïÎà¤ËÀßÄꤵ¤ì¤¿¡£

ÍÑḬ̂͸À­ÆÇÀ­¤ÏºÇÄãÍÑÎ̤òÅêÍ¿¤·¤¿´µ¼Ô¤Ë¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¤¬¡¢
Ãæ´ÖÍÑÎ̤òÅêÍ¿¤µ¤ì¤¿´µ¼Ô7Ì¾Ãæ3̾¤Ë¤Ï¥°¥ì¡¼¥É3¤Î²¼Î¡¤¬À¸¤¸¤¿¡£
ÍÑÎ̤ϲ¼Î¡¤¬À¸¤¸¤¿Î̤òͤ¨¤ÆÁýÎÌÅêÍ¿¤µ¤ì¤Ê¤«¤Ã¤¿¡£

¤¹¤Ù¤Æ¤Î´µ¼Ô¤ÏCAPIRI¤ÈÊü¼ÍÀþÎÅË¡¤ò¼õ¤±¤¿¸å¡¢4¡Á6½µÌܤ˺¬¼£ÅªÀÚ½ü½Ñ¤¬»Ü¹©¤µ¤ì¤¿¡£
ÉÂÍýÅªÃø¸ú¤¬´µ¼Ô4̾¤Ç¤¢¤ë21%¤Ëǧ¤á¤é¤ì¤ë°ìÊý¡¢¤µ¤é¤Ë5̾¤Ë¤ÏÈù¾®»ÄαÉÂÊѤΤߤ¬Ç§¤á¤é¤ì¤¿¡£

ƱÇî»Î¤é¤Ï¡¢¥¤¥ê¥Î¥Æ¥«¥ó½µ1²óÅêÍ¿¤ÈÊü¼ÍÀþÎÅË¡¤Ø¤Î¥«¥Ú¥·¥¿¥Ó¥ó500 mg/­Ö1Æü2²ó¤ÎÊ»ÍѤϡ¢
°ÂÁ´¤«¤ÄÍ­¸ú¤Ç¤¢¤ê¡¢¤³¤Î¥ì¥¸¥á¥ó¤ÎÂè­¶Áê»î¸³¤¬¼Â»Ü¤ËÃͤ¹¤ë¤È·ëÏÀÉÕ¤±¤Æ¤¤¤ë¡£

Ëܻ¤ËÉտ路¤¿µ­»öÃæ¤Ë¥Á¥ã¥Ú¥ë¥Ò¥ë¤Ë¤¢¤ë¥Î¡¼¥¹¥«¥í¥é¥¤¥ÊÂç³Ø°å³ØÉô¤ÎJoel E. TepperÇî»Î¤ª¤è¤Ó
Richard M. GoldbergÇî»Î¤¬¡¢¤³¤Î3¼ïÎàÁȤ߹ç¤ï¤»ÎÅË¡¤ÎÌäÂêÅÀ¤Ï
¤½¤ì¤¾¤ì¤Î¼£ÎÅË¡¤½¤ì¼«ÂΤ¬½ÅÂç¤Ê¾Ã²½´ÉÆÇÀ­¤òȯ´ø¤¹¤ë¤³¤È¤Ç¤¢¤ë¤Èµ­¤·¤Æ¤¤¤ë¡£
ξÇî»Î¤Ï¤µ¤é¤Ë¡¢¤³¤Î»î¸³¤Î´µ¼Ô´Ö¤ª¤¤¤Æ¼ê½Ñ¤Ë¤è¤ë½ÅÅÙ¹çÊ»¾É¤¬À¸¤¸¤¿¤³¤È¤â»ØÅ¦¤·¤Æ¤ª¤ê¡¢
¤³¤Î¤³¤È¤«¤éËܼ£ÎÅË¡¤¬Âè­·Áê»î¸³¼Â»Ü¤ò¹Íθ¤¹¤ëÁ°¤Ë²þÎɤµ¤ì¤ëɬÍפ¬¤¢¤ë¤³¤È¤ò¼¨º¶¤µ¤ì¤Æ¤¤¤ë¡£

HofheinzÇî»Î¤é¤Ï¡¢Æ±ÌôºÞ¤ÈÊü¼ÍÀþ¤È¤ÎÁê¸ßºîÍѤòºÇÂç¤È¤¹¤ë¤¿¤á¤ËÊü¼ÍÀþÎÅË¡¼Â»Ü¤È
¥¤¥ê¥Î¥Æ¥«¥óÅêÍ¿¤È¤Î»þ´Ö¤Ë¤ÏÃí°Õ¤òʧ¤Ã¤¿¤¬¡¢
¥«¥Ú¥·¥¿¥Ó¥ó¤ÎÅêÍ¿»þ´Ö¤Ë¤ÏƱÍͤÎÃí°Õ¤òʧ¤ï¤Ê¤«¤Ã¤¿¤³¤È¤òƱÇî»Î¤é¤Ïµ­¤·¤Æ¤¤¤ë¡£

TepperÇî»Î¤ª¤è¤ÓGoldbergÇî»Î¤Ï¡¢¸½¹Ô¤Î»î¸³¤Ï¡ÖÎɹ¥¤Ë¼Â»Ü¤µ¤ì¤¿Î×¾²»î¸³¡×¤Ç¤Ï¤¢¤ë¤¬¡¢
¡ÖÆÀ¤é¤ì¤¿Åú¤¨¤è¤ê¤â¿¤¯¤Îµ¿ÌäÅÀ¤¬Ä󵯤µ¤ì¤Æ¤¤¤ë¡×¤È·ëÏÀÉÕ¤±¤Æ¤¤¤ë¡£

J Clin Oncol 2005;23:1350-1357.

¡öÃí°Õ¡Ë¸¶Ê¸¤Ï±Ñ¸ìʸ¤È¤Ê¤ê¤Þ¤¹¤Î¤Ç¡¢ÆüËܸìÌõ¤Ï¤¢¤¯¤Þ¤Ç»²¹Í¤È¤·¤Æ¤´ÍøÍѴꤤ¤Þ¤¹¡£

http://www.kwn-rmn.jp/cgi-bin/taiho/news.cgi?mode=jpview&num=717

3 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2006/09/12(²Ð) 13:20
¥á¥é¥Î¡¼¥Þ´µ¼ÔÂоݡ¦Âè2Áê»î¸³¡¦¥×¥é¥¤¥Þ¥ê¡¼¥¨¥ó¥É¥Ý¥¤¥ó¥ÈãÀ®¡ª

http://www.biotoday.com/view.cfm?n=15002

Synta Pharmaceuticals¼Ò¤Ï¡¢¥¹¥Æ¡¼¥¸4¥á¥é¥Î¡¼¥Þ´µ¼Ô81¿Í¤òÂоݤˤ·¤¿
¥Ò¡¼¥È¥·¥ç¥Ã¥¯¥¿¥ó¥Ñ¥¯¼Á70¡Êheat shock protein 70¡¢Hsp70¡ËͶƳºÞ¡¦STA-4783¤Î
¥×¥é¥»¥ÜÂÐ¾ÝÆó½ÅÌÕ¸¡¸å´üÂè2Áê»î¸³¤Ç¥×¥é¥¤¥Þ¥ê¡¼¥¨¥ó¥É¥Ý¥¤¥ó¥È¤òãÀ®¤·¤¿¤Èȯɽ¤·¤Þ¤·¤¿¡£

¼£Î꤯ñ¤È¤µ¤ì¤Æ¤¤¤ë¥¹¥Æ¡¼¥¸4¤Î¥á¥é¥Î¡¼¥Þ¤òÂоݤˤ·¤¿¥×¥é¥»¥ÜÂÐ¾ÝÆó½ÅÌÕ¸¡»î¸³¤Ç
STA-4783¤ÎÌÀ³Î¤ÊÌô¸ú¤ò¼¨¤¹¤³¤È¤ËÀ®¸ù¤·¤Þ¤·¤¿¡£

¥È¥Ã¥×¥¤¥ó¥¿¥Ó¥å¡¼
¡¡¡¡1²óÌÜ¡¡http://report.biotoday.com/179.php
¡¡¡¡2²óÌÜ¡¡http://report.biotoday.com/181.php
¡¡¡¡3²óÌÜ¡¡http://report.biotoday.com/182.php
¡¡¡¡4²óÌÜ¡¡http://report.biotoday.com/183.php
¡¡¡¡ºÇ½ª²ó http://report.biotoday.com/344.php

4 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2007/11/13(²Ð) 17:37
»ä¤Ï¡¢

5 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2007/11/28(¿å) 14:25
Åà·ëÍ»²ò²õ»àÎÅË¡¡¢¿Õ¡´â´µ¼Ô¤Îžµ¢Îɹ¥
http://www.biotoday.com/view.cfm?n=23522

¥á¥¤¥è¡¼¥¯¥ê¥Ë¥Ã¥¯¤ÇÅà·ëÍ»²ò²õ»àÎÅË¡¤ò¼õ¤±¤¿¿Õ¡´â´µ¼Ô¤Îžµ¢¤ÏÎɹ¥
¿Õ¡´â¤ËÂФ·¤ÆÅà·ëÍ»²ò²õ»àÎÅË¡¡Êcryoablation¡Ë¤ò¼õ¤±¤¿62¿Í¤Î´µ¼Ô¤Î¥ì¥Ó¥å¡¼¤Ç
Îɹ¥¤Ê·ë²Ì¤¬ÆÀ¤é¤ì¤Æ¤¤¤ë¤ÈMayo Clinic¤Î¸¦µæ¼ÔÅù¤¬³Ø²ñ¤Çȯɽ¤·¤Þ¤·¤¿¡£

6 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2008/11/14(¶â) 22:55
´ÁÊýÌô¤ÎÀ®Ê¬¥¢¡¼¥Æ¥ß¥·¥Ë¥ó(¥¢¥ë¥Æ¥ß¥·¥Ë¥ó)¤«¤é¡¤¶¯ÎϤʹ³´âºÞ
News Release from University of Washington on October 13, 2008.

http://medieigo.com/weeklytopic.php?id=117

´ÁÊýÌô¤ÎÀ®Ê¬¥¢¡¼¥Æ¥ß¥·¥Ë¥ó¤«¤é¡¤¶¯ÎϤʹ³´âºÞ¤¬À¸¤Þ¤ì¤Ä¤Ä¤¢¤ë¡£
¥¢¡¼¥Æ¥ß¥·¥Ë¥ó¤ÏÅ´¤ò´Þ¤à´Ä¶­¤ÇÆÇÀ­¤ò¶¯¤¯È¯´ø¤¹¤ë¤¿¤á¡¤
Å´¤¬Ë­É٤ʴâºÙ˦¤ò¡¤ÉûºîÍѤò¤¢¤Þ¤êµ¯¤³¤µ¤º¤Ë»¦¤¹¤³¤È¤¬¤Ç¤­¤ë¡£
Ä̾´âºÙ˦¤Ï¡ÖÅ´¤¬É¬ÍספȤ¤¤¦¿®¹æ¤òȯ¤¹¤ë¥¿¥ó¥Ñ¥¯¼Á¤òºÙ˦ɽÌ̤˽и½¤µ¤»¡¤
¤³¤ì¤ËÈ¿±þ¤·¤Æ½¸¤á¤é¤ì¤¿Å´¤ò¥¿¥ó¥Ñ¥¯¼Á¤â¤í¤È¤â°û¤ß¹þ¤ó¤Ç¤·¤Þ¤¦¡£
¸¦µæ¼Ô¤é¤Ï¤³¤Î¥¿¥ó¥Ñ¥¯¼Á¤Ë¤¯¤Ã¤Ä¤¯Êª¼Á¤ò¥¢¡¼¥Æ¥ß¥·¥Ë¥ó¤ËÅëºÜ¤·¡¤
´âºÙ˦¤ÎÃæ¤Ë¸úΨ¤è¤¯Åþ㤹¤ë¤è¤¦¤Ë¤·¤¿¡£
¸¦µæ¼Ô¤é¤Ï¡Ö´âºÙ˦¤ËÇúÃÆ¤ò»Å³Ý¤±¤ë¤è¤¦¤Ê¤â¤Î¡×¤È¸ì¤Ã¤Æ¤¤¤ë¡£

»²¹Í¥µ¥¤¥È
http://www.1kampo.com/topics-13(artesunate).html

7 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2009/01/17(ÅÚ) 23:33
¥Ï¡¼¥Ð¡¼¥ÉÂç¡¢¼ù¾õºÙ˦¤òÂçÎ̤˳èÀ­²½¤µ¤»¤ëµ»½Ñ³«È¯¡£

http://slashdot.jp/science/09/01/16/0138240.shtml

¡Ö¼ù¾õºÙ˦ÎÅË¡¡×¤Î¸¦µæÁ°¿Ê¤Ø ¡£¤Þ¤À¥Þ¥¦¥¹¤Ç¤¹¤¬¡£

¼Â¸³¤Çľ·Â 8.5 mm ¤Î¥·¥ê¥ó¥À¡¼¤ò¥Þ¥¦¥¹¤ËËä¤á¹þ¤ß¡¢¤½¤Î 2 ½µ´Ö¸å¤Ë
Èó¾ï¤Ë¿¯¹¶À­¤Î¹â¤¤¥á¥é¥Î¡¼¥ÞºÙ˦¤òÃíÆþ¤·¤¿¤È¤³¤í¡¢
¶õ¤Î¥·¥ê¥ó¥À¡¼¤òËä¤á¹þ¤ó¤À¥Þ¥¦¥¹¤Ï 18 Æü°ÊÆâ¤ËÂ礭¤Ê¼ðá礬¤Ç¤­¤¿¤¬¡¢
¼£ÎÅÌÜŪ¤Î¥·¥ê¥ó¥À¡¼¤òËä¤á¹þ¤ó¤À¥Þ¥¦¥¹¤Î 90 % ¤Ï¼£Ìþ¤·¤¿¡£
½¾Íè¤Î¼ù¾õºÙ˦ÎÅË¡¤Ç¤Ï¤³¤ì¤Û¤É¹â¤¤À¸Â¸Î¨¤Ï¤ß¤é¤ì¤Ê¤¤¤¬¡¢
Ëä¤á¹þ¤ó¤À¥·¥ê¥ó¥À¡¼¤Ë¤è¤Ã¤ÆÂçÎ̤μù¾õºÙ˦¤Î³èÀ­²½¤ò¼Â¸½¤·¤¿¤³¤È¤¬
¥Ö¥ì¥¤¥¯¥¹¥ë¡¼¤È¤Ê¤Ã¤¿¤È¤Î¤³¤È¡£

8 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2009/06/01(·î) 10:14
¹¹Ç¯´ü½÷À­¤Î¥Û¥ë¥â¥óÎÅË¡¡¢ÇÙ¤¬¤óȯ¾É¤¹¤ë¤È»à˴ΨÁý
http://www.afpbb.com/article/life-culture/health/2607414/4212398

Chlebowski»á¤é¤Î¸¦µæ¥Á¡¼¥à¤¬¡¢ÊÆÎ×¾²¼ðáç³Ø²ñASCO¤Îǯ¼¡²ñµÄ¤Çȯɽ¡£
¥¨¥¹¥È¥í¥²¥ó¤È¥×¥í¥²¥¹¥Á¥ó¤È¤¤¤¦2¼ïÎà¤Î½÷À­¥Û¥ë¥â¥ó¤ò¾ûºÞ¤Ë¤·¤¿¥Û¥ë¥â¥óÊä½¼Ìô
Ž¢¥×¥ì¥ó¥×¥í¡ÊPrempro¡ËŽ£¤Ë¤Ä¤¤¤Æ¡¢5ǯȾ¤Ë¤ï¤¿¤ê¡¢ÇÙ¤¬¤ó¤ÎȯÀ¸Î¨¤È»à˴Ψ¤Ë¤Ä¤¤¤Æ¡¢
¥×¥ì¥ó¥×¥í¤Ë¤è¤ë¥Û¥ë¥â¥ó¼£ÎŤò¹Ô¤Ã¤¿¥°¥ë¡¼¥×¤Èµ¶Ìô¤òÅêÍ¿¤·¤¿¥°¥ë¡¼¥×¤òÈæ³Ó¤·¤¿¡£

¤½¤Î·ë²Ì¡¢ÇÙ¤¬¤ó¤ÎȯÀ¸Î¨¼«ÂΤˤÏ2¤Ä¤Î¥°¥ë¡¼¥×¤Ë°ã¤¤¤Ï¤¢¤Þ¤ê¸«¤é¤ì¤Ê¤«¤Ã¤¿¤¬¡¢
ȯ¾É¤·¤¿¾ì¹ç¤Î»à˴Ψ¤Ï¥Û¥ë¥â¥óÎÅË¡¤ò¼õ¤±¤¿½÷À­¤Î¤Û¤¦¤¬2Çܤâ¹â¤«¤Ã¤¿¡£
¤Þ¤¿¡¢¹¹Ç¯´ü¤Î½÷À­¤ÇÇÙ¤¬¤ó¤Ë¤«¤«¤Ã¤Æ¤¤¤Æ¡¢¸å¤«¤é¥Û¥ë¥â¥ó¼£ÎŤâ¼õ¤±¤¿¾ì¹ç¡¢
ÇÙ¤¬¤ó¤Ë¤è¤ë»à˴Ψ¤Ï¤Û¤«¤Î½÷À­¤è¤ê¤â61%¤â¹â¤«¤Ã¤¿¡£

9 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2009/06/11(ÌÚ) 15:42
À¸³è½¬´·¤Î²þÁ±¤Ç´â¥ê¥¹¥¯¤òÂçÉý¤Ë·Ú¸º²Äǽ
http://health.nikkei.co.jp/hsn/news.cfm?i=20090611hj001hj

ÆÃÄê¤Î¿Í¤Ï¤¤¤º¤ìɬ¤º´â¤Ë¤Ê¤ê¡¢¤½¤Î±¿Ì¿¤òÊѤ¨¤ë¤³¤È¤Ï¤Ç¤­¤Ê¤¤¤È¹Í¤¨¤Æ¤¤¤ë¿Í¤â¤¤¤ë¤¬¡¢
¼ÂºÝ¤Ï´â¤Ë¤Ê¤ê¤ä¤¹¤¤¿Í¤Ç¤âÀ¸³è½¬´·¤Î²þÁ±¤Ë¤è¤Ã¤ÆÂçÉý¤Ë¥ê¥¹¥¯¤ò·Ú¸º¤Ç¤­¤ë¤È¤¤¤¦¡£
ÊÆ¹ñ´â¸¦µæ¶¨²ñ¡ÊAICR¡Ë¤ÎKaren Collins»á¤Ï¡Ö¿©»ö¡¢Âνš¢±¿Æ°¤Î£³¤Ä¤ò
²þÁ±¤¹¤ë¤³¤È¤Ë¤è¤ê´â¤ÎÌó£³Ê¬¤Î£±¤òËɤ°¤³¤È¤¬¤Ç¤­¡¢¤µ¤é¤Ë¶Ø±ì¤òÄɲ乤ì¤Ð
¸½ºß¤Î´â¤ÎȾʬ°Ê¾å¤òͽËɤ¹¤ë¤³¤È¤¬²Äǽ¤À¡×¤È½Ò¤Ù¤Æ¤¤¤ë¡£

10 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2009/06/11(ÌÚ) 15:50
¡Ö¤¬¤óºÙ˦¤È¤Î¶¦À¸¡×¤Ï¡ÖËÐÌǡפè¤ê¸ú²ÌŪ¡§¿·¤·¤¤¼£ÎÅË¡
http://wiredvision.jp/news/200906/2009061123.html

¤¬¤ó¤òưŪ¤Ë¿Ê²½¤¹¤ë¥·¥¹¥Æ¥à¤È¤·¤ÆÂª¤¨¤ë¿·À¤Âå¤Î¸¦µæ¼Ô¤Ç¤¢¤ë¥â¥Õ¥£¥Ã¥È¤¬¤ó¥»¥ó¥¿¡¼¤Î
Robert Gatenby»á¤Ï¡¢¤¢¤¨¤Æ¼çÍפòĹ´ü¤Îç±Ãå¾õÂ֤˻ý¤Á¹þ¤àÊý¤¬¤¦¤Þ¤¯¹Ô¤¯²ÄǽÀ­¤¬¤¢¤ë
¤È¸ì¤ë¡£

¤¬¤ó¤ÎĹ´üŪ°ÂÄêÀ­¤Ë´Ø¤¹¤ëGatenby»á¤Î¥â¥Ç¥ë¤Ï¡¢¡ØCancer Research¡Ù»ï¤Î6·î1Æü¹æ¤Ë
·ÇºÜ¤µ¤ì¤¿¡£Gatenby»á¤Ï¡¢¡ØNature¡Ù»ï5·î28Æü¹æ¤Ë´ó¤»¤¿¥¨¥Ã¥»¥¤¤Ç¤â¡¢
¼«¿È¤Î¥¢¥×¥í¡¼¥Á¤ò¾Ò²ð¤·¤Æ¤¤¤ë¡£

¥Þ¥¦¥¹¤ÎÍñÁ㤬¤ó¤òÎã¤Ë¤È¤ë¤È¡¢¤­¤ï¤á¤ÆÂçÎ̤ÎÌôºÞ¤òÅêÍ¿¤·¤¿¾ì¹ç¡¢
¼ðá礬¾ÃÌǤ¹¤ë¤Î¤Ç¡¢´°¼£¤Ç¤­¤¿¤è¤¦¤Ë¸«¤¨¤Þ¤¹¡£
¤·¤«¤·¿ô½µ´Ö¸å¤Ë¤ÏºÆÈ¯¤·¡¢¥Þ¥¦¥¹¤ò»à¤Ë»ê¤é¤·¤á¤Þ¤¹¡£¤³¤ì¤¬°ìÈÌŪ¤ÊÀ®¤ê¹Ô¤­¤Ç¤¹¡£

¤ï¤ì¤ï¤ì¤Ï¡¢ÌôºÞ¤ÎÎ̤ò¸º¤é¤·¡¢É¬Íפʻþ¤À¤±ÅêÍ¿¤·¤Þ¤·¤¿¡£¤³¤ì¤Ë¤è¤ê¡¢
¼ðáç¤ò°ÂÄꤷ¤¿¾õÂÖ¤ËÊݤÁ¡¢¥Þ¥¦¥¹¤ò¤¤¤Ä¤Þ¤Ç¤âÀ¸¤«¤·¤Æ¤ª¤¯¤³¤È¤¬¤Ç¤­¤Þ¤·¤¿¡£

11 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2009/07/03(¶â) 16:17
ºÙ¶Ý¤òÍøÍѤ·¤¿´â¼£ÎÅ
http://www.nytimes.com/2009/06/29/health/research/29drug.html?_r=3&hp

¥ª¡¼¥¹¥È¥é¥ê¥¢¤Î¸¦µæ¼Ô¤¬³«È¯¤·¤¿´â¼£ÎŤο·Ìô¤¬¡¢Æ°Êª¼Â¸³¤Ç¶Ã¤¯¤Ù¤­¸ú²Ì¤ò¼¨¤·¤¿¡£
¼Â¸³¤Ï¡¢¿Ê¹ÔÀ­¤Ç°­À­¤¬¹â¤¯¡¢Â¿¤¯¤ÎÌô¤ËÄñ¹³ÎϤΤ¢¤ë¥Ò¥È¤Î»ÒµÜ´âºÙ˦¤ò¥Þ¥¦¥¹¤Ë°Ü¿¢¤·¤Æ¹Ô¤Ã¤¿¤â¤Î¡£¼£ÎŤò»Ü¤µ¤Ê¤«¤Ã¤¿¥Þ¥¦¥¹¤Ï£±¥ö·î¸å¤Ë¤Ï»àË´¤·¤¿¤¬¡¢
¤³¤Î¿·Ìô¼£ÎŤò¹Ô¤Ã¤¿¥Þ¥¦¥¹¤Ë¤Ä¤¤¤Æ¤Ï¡¢¤¹¤Ù¤Æ£·£°Æü¤Ç¼ðá礬¾ÃÌǤ·¤¿¤È¤¤¤¦¡£


¼¡¡¡¿·Ãå¥ì¥¹¤Îɽ¼¨¡¡¡¡TOP¤Ø
̾Á° ¡§ E-mail(¾Êά²Ä) ¡§
Ãç´ÖƱ»Î¡¦Èó¸ø³«¤Î·Ç¼¨ÈÄ,¥á¡¼¥ë¸ò´¹,
¥Ö¥í¥°,¥¢¥Ð¥¿¡¼,¾·ÂÔ¾õޥޥޥ
¡¡´â·Ç¼¨ÈĤο·¥³¡¼¥Ê¡¼¡¡
¡¡¤¬¤óSNS

(C) ¥¿¥«¥Ò¥í¡÷¤ß¤Á¤Î¤¯·Ç¼¨ÈÄ [12ch BBS 1.06²þ]
read.cgi²þ¦Â£±Ver.1.01